| For: | Qian XJ, Wen ZM, Huang XM, Feng HJ, Lin SS, Liu YN, Li SC, Zhang Y, Peng WG, Yang JR, Zheng ZY, Zhang L, Zhang DW, Lu FM, Liu LJ, Pan WD. Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin. World J Gastroenterol 2023; 29(8): 1359-1373 [PMID: 36925461 DOI: 10.3748/wjg.v29.i8.1359] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i8/1359.htm |
| Number | Citing Articles |
| 1 |
Dipanwita Biswas, Suvradeep Mitra, Aravind Sekar, Swapnesh Sahu, Lileswar Kaman. Giant Masses in a Non-Cirrhotic Liver: All That Look Epithelial Are Not Carcinoma. Cureus 2026; doi: 10.7759/cureus.110020
|
| 2 |
Ivan Tattoli, Aimee Rachel Mathew, Antonella Verrienti, Lucia Pallotta, Carola Severi, Fausto Andreola, Virve Cavallucci, Mauro Giorgi, Mara Massimi, Lapo Bencini, Marco Fidaleo. The Interplay between Liver and Adipose Tissue in the Onset of Liver Diseases: Exploring the Role of Vitamin Deficiency. Cells 2024; 13(19) doi: 10.3390/cells13191631
|
| 3 |
Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang. Value of des-gamma-carboxy prothrombin in comprehensive management of hepatocellular carcinoma. World Chinese Journal of Digestology 2026; 34(2) doi: 10.11569/wcjd.v34.i2.110
Abstract(108) |
Core Tip(111) |
Full Article(HTML)(514)
|
Times Cited (0)
|
Total Visits (657)
|
Open
|
| 4 |
Yinqiu Wang, Meihui Liu, Zihan Xie, Junjie Lin, Shucheng Du, Chao Zhang, Zixuan Wang, Yufeng Gao. Assessment of the diagnostic performance and influencing factors of AFP and PIVKA-II in hepatocellular carcinoma. Discover Oncology 2026; 17(1) doi: 10.1007/s12672-026-05051-8
|
| 5 |
Xi-Ming Wang, Hui-Gang Li, Jin-Xin Xu, Xiang Wu, Hong Li. Protein induced by vitamin K absence or antagonist-II in hepatocellular carcinoma with normal alpha-fetoprotein: Current advances and controversies. World Journal of Gastrointestinal Oncology 2026; 18(5): 118297 doi: 10.4251/wjgo.v18.i5.118297
|
| 6 |
Yanhui Shi, Hongli Yang, Xue Bai, Xiaoyan Liu, Qiang Li, Wenjun Du. Female and diabetes are risk factors for alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II negative in hepatocellular carcinoma. Medicine 2024; 103(42) doi: 10.1097/MD.0000000000040100
|
| 7 |
Kunyu Zhao, Lili Wu, Yu Wu, Qianqian Jiang, Mengmeng Zhu, Suzhen Jiang, Chao Zhang, Fengmin Lu. Functional cure for chronic hepatitis B: A state of immune control over cccDNA persistence. Infectious Diseases & Immunity 2026; 6(2) doi: 10.1097/ID9.0000000000000181
|
| 8 |
Bin Wei, Yalin Zheng, Lixin Li, Limei Luo, Ying Guo. Establishment of sex-specific reference intervals for PIVKA-II in Southwest China: A real-world data analysis. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 2025; 62(3) doi: 10.1177/00045632241306074
|
| 9 |
Kuan-Jung Huang, Chun-Ting Ho, Pei-Chang Lee, San-Chi Chen, Chien-An Liu, Shu-Cheng Chou, I-Cheng Lee, Yi-Hsiang Huang, Jiing-Chyuan Luo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels. Journal of the Chinese Medical Association 2025; 88(12) doi: 10.1097/JCMA.0000000000001305
|